Related Experiment Video
Updated: Aug 14, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Intravenous iron therapy: well-tolerated, yet not harmless
G Sengölge1, W H Hörl, G Sunder-Plassmann
1Department of Medicine III, Medical University Vienna, Austria. Guerkan.Sengoelge@meduniwien.ac.at
Intravenous iron therapy is crucial for chronic renal failure patients to maintain hemoglobin. While generally safe and effective, potential effects on infection and atherosclerosis warrant careful consideration.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Chronic renal failure (CRF) often necessitates erythropoietic agents and iron supplementation to achieve target hemoglobin levels (e.g., >11 g/dL).
- Intravenous (IV) iron administration is recognized as more effective than oral iron for managing anemia in CRF patients.
- Commonly used IV iron formulations include iron(III)-hydroxide-sucrose complex (iron sucrose) and iron(III)-sodium-gluconate in sucrose (iron gluconate), generally demonstrating good tolerability.
Purpose of the Study:
- To review the efficacy and safety of intravenous iron therapy in patients with chronic renal failure.
- To discuss the potential adverse effects of IV iron, particularly concerning non-transferrin bound labile iron and its implications.
- To evaluate the association between iron therapy and risks of infection or atherosclerosis.
Main Methods:
- Review of existing literature on intravenous iron therapy in chronic renal failure.
- Analysis of studies investigating the effects of IV iron on cellular components and cytokines.
- Examination of clinical trial data regarding the safety and tolerability of iron sucrose.
Main Results:
- IV iron sucrose and iron gluconate are effective and generally well-tolerated for anemia management in CRF.
- IV iron can influence endothelial cells, polymorphonuclear leukocytes, and cytokines, potentially linked to labile iron.
- Evidence regarding iron's role in infection and atherosclerosis is conflicting; a recent trial indicated iron sucrose is safe for iron deficiency treatment and maintenance.
Conclusions:
- Intravenous iron therapy is essential for managing anemia in chronic renal failure patients.
- While generally safe, the potential impact of labile iron requires careful monitoring and consideration.
- Iron therapy should be administered judiciously when indicated, without undue fear, based on current evidence.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Drug Toxicity: Overview
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
Pharmaceutical Poisoning: Treatment Strategies
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
